Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.

Mita AC, Mita MM, Rowinsky EK.

Clin Colorectal Cancer. 2004 Jul;4(2):107-23. Review.

PMID:
15285818
2.
3.

Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.

Amador ML, Hidalgo M.

Clin Colorectal Cancer. 2004 May;4(1):51-62. Review.

PMID:
15207021
4.

Novel targets for anticancer treatment development in colorectal cancer.

Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J.

Clin Colorectal Cancer. 2006 Nov;6(4):265-72. Review.

PMID:
17241511
5.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.

Adams R, Brown E, Brown L, Butler R, Falk S, Fisher D, Kaplan R, Quirke P, Richman S, Samuel L, Seligmann J, Seymour M, Shiu KK, Wasan H, Wilson R, Maughan T; FOCUS4 Trial Investigators.

Lancet Gastroenterol Hepatol. 2018 Mar;3(3):162-171. doi: 10.1016/S2468-1253(17)30394-1. Epub 2017 Dec 16.

6.

Targeting signal transduction pathways in colorectal cancer--more than skin deep.

Cohen SJ, Cohen RB, Meropol NJ.

J Clin Oncol. 2005 Aug 10;23(23):5374-85. Epub 2005 Jul 5. Review.

PMID:
15998904
7.

Therapeutics targeting signal transduction for patients with colorectal carcinoma.

de Bono JS, Rowinsky EK.

Br Med Bull. 2002;64:227-54. Review.

PMID:
12421735
8.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
9.

The new paradigm in the treatment of colorectal cancer: are we hitting the right target?

Baranda J, Williamson S.

Expert Opin Investig Drugs. 2007 Mar;16(3):311-24. Review.

PMID:
17302526
10.

Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.

Sundaramoorthy P, Ramasamy T, Mishra SK, Jeong KY, Yong CS, Kim JO, Kim HM.

Acta Biomater. 2016 Sep 15;42:220-231. doi: 10.1016/j.actbio.2016.07.006. Epub 2016 Jul 6.

PMID:
27395829
11.

Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.

Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H.

World J Gastroenterol. 2006 Sep 21;12(35):5635-43.

12.
13.

Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.

Hamid O.

J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):52-8. Review.

PMID:
14965154
14.

The role of the PI3K pathway in colorectal cancer.

Papadatos-Pastos D, Rabbie R, Ross P, Sarker D.

Crit Rev Oncol Hematol. 2015 Apr;94(1):18-30. doi: 10.1016/j.critrevonc.2014.12.006. Epub 2014 Dec 25. Review.

PMID:
25591826
15.

The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Lieu C, Kopetz S.

Clin Colorectal Cancer. 2010 Apr;9(2):89-94. doi: 10.3816/CCC.2010.n.012. Review.

17.

Monoclonal antibodies in the treatment of advanced colorectal cancer.

Capdevila J, Saura C, Macarulla T, Casado E, Ramos FJ, Tabernero J.

Eur J Surg Oncol. 2007 Dec;33 Suppl 2:S24-34. Epub 2007 Nov 5. Review.

PMID:
17981431
18.

The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.

Forsythe N, Refaat A, Javadi A, Khawaja H, Weir JA, Emam H, Allen WL, Burkamp F, Popovici V, Jithesh PV, Isella C, Labonte MJ, Mills IG, Johnston PG, Van Schaeybroeck S.

Mol Cancer Ther. 2018 Jun;17(6):1280-1290. doi: 10.1158/1535-7163.MCT-17-0603. Epub 2018 Feb 26.

19.

Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I.

World J Gastroenterol. 2007 Nov 28;13(44):5877-87. Review.

Supplemental Content

Support Center